Parkinson’s disease

The prevalence of Parkinson’s disease is projected to grow steadily in seven major markets, driven by ageing populations and the…

The 7MM pipeline in Parkinson’s disease shifts focus to neuroprotective and disease-modifying therapies, aiming to address unmet…

Eligible for 180 days of generic drug exclusivity for Amantadine extended release capsules, 68.5 mg

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus. Studies have demonstrated that ZYIL1 is…

Understanding the integrated stress response is an important next step towards grasping the importance of target engagement…

ZYIL1 is a novel oral small molecule NLRP3 inhibitor. Studies have demonstrated that ZYIL1 is highly potent and can suppress…

506 patients completed enrolment across 84 sites in the US, Europe and India

Amneal’s IPX203 is an oral extended-release (ER) capsule formulation of levodopa that is designed to sustain levodopa plasma…

The need for disease-modifying therapies is one of the highest unmet needs and if a curative or disease-modifying agent was…

If any disease-modifying therapy managed to enter the PD market, it would revolutionise the treatment paradigm and generate a…